Neumora Therapeutics, Inc.
Business
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for neuropsychiatric, neurodegenerative, and metabolic disorders using brain-penetrant chemistry and a precision neuroscience platform. The company is advancing multiple programs including navacaprant (Phase 3 for major depressive disorder), NMRA-511 (Phase 1b for Alzheimer's agitation), NMRA-898 (Phase 1 for schizophrenia), and NMRA-215 (preclinical for obesity), alongside earlier-stage programs licensed from academic and industry partners. Neumora operates as a fully virtual company, outsourcing manufacturing to contract organizations and planning to build commercial infrastructure as programs advance.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 176 | 201 | 143 | 92 | |
| General and administrative | 60 | 63 | 45 | 31 | |
| Acquired in-process research and development | 5 | 0 | 64 | 13 | |
| Total operating expenses | 241 | 263 | 252 | 136 | |
| Loss from operations | −241 | −263 | −252 | −136 | |
| Interest income | 8 | 20 | — | — | |
| Interest expense | −3 | 0 | — | — | |
| Other expense, net | −767,000 | −78,000 | −170,000 | 405,000 | |
| Total other income | 4 | 20 | 16 | 5 | |
| Net loss before income taxes | −237 | −244 | −236 | −131 | |
| Provision for income taxes | 130,000 | 178,000 | 268,000 | — | |
| Net loss | −237 | −244 | −236 | −131 | |
| Unrealized gain (loss) on marketable securities | −62,000 | 138,000 | 698,000 | −774,000 | |
| Comprehensive loss | −237 | −244 | −235 | −132 | |
| Net loss per share, basic | −1.45 | −1.53 | −3.63 | −4.81 | |
| Net loss per share, diluted | −1.45 | −1.53 | −3.63 | −4.81 | |
| Weighted-average shares outstanding, basic | 163 | 159 | 65 | 27 | |
| Weighted-average shares outstanding, diluted | 163 | 159 | 65 | 27 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 183 | 142 | 374 | 241 | — | |
| Restricted cash | — | 1 | — | 50,000 | — | |
| Short-term marketable securities | — | 165 | 80 | 131 | — | |
| Prepaid expenses and other current assets | 8 | 5 | 24 | 16 | — | |
| Total current assets | 191 | 314 | 478 | 388 | — | |
| Property and equipment, net | 40,000 | 1 | 2 | 2 | — | |
| Operating lease right-of-use assets | 417,000 | 2 | 5 | 8 | — | |
| Other assets | 53,000 | — | — | 3 | — | |
| Total assets | 191 | 317 | 496 | 426 | — | |
| Accounts payable | 3 | 3 | 337,000 | 7 | — | |
| Accrued liabilities | 29 | 25 | 21 | 12 | — | |
| Early exercise liability, current portion | — | 133,000 | 139,000 | 2 | — | |
| Operating lease liabilities, current portion | 284,000 | 2 | 3 | 3 | — | |
| Total current liabilities | 32 | 30 | 25 | 24 | — | |
| Long term debt, net | 55 | — | — | — | — | |
| Operating lease liabilities, noncurrent | 193,000 | — | 2 | 5 | — | |
| Early exercise liability, net of current portion | — | 22,000 | 155,000 | 628,000 | — | |
| Total liabilities | 87 | 30 | 27 | 29 | — | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock, $0.0001 par value; 700,000 shares authorized as of December 31, 2025 and December 31, 2024; 174,260 and 161,710 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 17,000 | 16,000 | 16,000 | 3,000 | — | |
| Additional paid-in capital | 1,288 | 1,234 | 1,173 | 21 | — | |
| Accumulated other comprehensive income | — | 62,000 | −76,000 | −774,000 | — | |
| Accumulated deficit | −1,184 | −947 | −703 | −468 | — | |
| Total stockholders' equity | 104 | 287 | 469 | −447 | −325 | |
| Total liabilities and stockholders' equity | 191 | 317 | 496 | 426 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Net loss | −237 | −244 | −236 | −131 | |
| Stock-based compensation | 30 | 40 | 17 | 8 | |
| Non-cash operating lease expense | 2 | 3 | 3 | 2 | |
| Depreciation and amortization | 208,000 | 631,000 | 700,000 | 600,000 | |
| Net accretion of investments in marketable securities | −3 | −6 | −4 | −708,000 | |
| Impairment of held for sale assets | 595,000 | 0 | — | — | |
| Loss on disposal of property and equipment | 47,000 | 0 | — | — | |
| Amortization of debt issuance costs and accretion of final payment fee | 492,000 | 0 | — | — | |
| Amortization and write-off of deferred debt issuance costs | 717,000 | 0 | — | — | |
| Other noncash expenses | 32,000 | 23,000 | — | — | |
| Prepaid expenses and other current assets | −3 | 16 | −11 | −4 | |
| Accounts payable | 71,000 | 3 | −581,000 | −1 | |
| Accrued liabilities | 4 | 7 | 6 | −2 | |
| Operating lease liabilities | −2 | −3 | −3 | −2 | |
| Other assets | −53,000 | 0 | — | 1 | |
| Net cash used in operating activities | −206 | −183 | −163 | −115 | |
| Purchases of marketable securities | −83 | −312 | −109 | −226 | |
| Cash paid for acquisition of assets | 0 | −775,000 | −5 | −13 | |
| Proceeds from maturities of marketable securities | 251 | 242 | 178 | 72 | |
| Proceeds from sale of property and equipment | 200,000 | 0 | — | — | |
| Net cash provided by (used in) investing activities | 169 | −71 | 64 | −168 | |
| Proceeds from term loan, net | 57 | 0 | — | — | |
| Proceeds from exercise of stock options | 0 | 7 | 3 | 3 | |
| Proceeds from employee stock purchase plan purchases | 275,000 | 427,000 | — | — | |
| Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs | 20 | 14 | — | — | |
| Net cash provided by financing activities | 77 | 22 | 232 | 116 | |
| Net change in cash and cash equivalents and restricted cash | 39 | −232 | 133 | −167 | |
| Cash paid for interest | 2 | 0 | — | — | |
| Cash paid for income taxes | 323,000 | 473,000 | — | — | |
| Principal amount of debt extinguished upon conversion to common stock | 4 | 0 | — | — | |
| Debt issuance costs reclassified to equity in connection with conversion | 112,000 | 0 | — | — | |
| Right-of-use-asset in connection with new operating lease agreement | 532,000 | 0 | 192,000 | 9 | |
| Operating lease liability in connection with new lease agreement | 505,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Neumora Therapeutics, Inc.'s CIK number?
Neumora Therapeutics, Inc.'s SEC CIK number is 0001885522 (1885522). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Neumora Therapeutics, Inc.'s SEC filings?
All of Neumora Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Neumora Therapeutics, Inc. last report earnings?
Neumora Therapeutics, Inc. (NMRA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210310). This is Neumora Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Neumora Therapeutics, Inc.'s most recent earnings 8-K?
Neumora Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210310. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Neumora Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →